Patients' preferences and willingness-to-pay for disease-modifying therapies
| Autor: | Jerome W Freeman, Surachat Ngorsuraches, Diana I. Brixner, Natasha Frost, Jane R. Mort, James R Clem |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Multiple Sclerosis Psychometrics Discrete choice experiment Disease 03 medical and health sciences Route of administration 0302 clinical medicine Willingness to pay Recurrence Medicine Humans Immunologic Factors 030212 general & internal medicine Adverse effect Multinomial logistic regression Aged Choice set business.industry Patient Preference General Medicine Middle Aged Neurology Disease Progression Lower cost Female Neurology (clinical) Health Expenditures business 030217 neurology & neurosurgery |
| Zdroj: | Multiple sclerosis and related disorders. 35 |
| ISSN: | 2211-0356 |
| Popis: | Background While disease-modifying therapies (DMTs) for multiple sclerosis (MS) treatments are costly, patient valuation of DMTs has not been examined. The objective of this study was to examine patients' preferences and willingness-to-pay (WTP) for DMTs. Methods Six attributes (i.e., number of relapses, percentage of disability progression, percentage of severe adverse events, route of administration, frequency of administration, and out-of-pocket cost) and their levels were used to develop a discrete choice experiment questionnaire. Each questionnaire comprised seven choice sets and each choice set contained two hypothetical DMTs and an opt-out alternative. A total of 1,200 U.S. patients with MS were asked to choose a DMT option or opt-out in each choice set. Multinomial logit model was used to determine relative preferences of each attribute. WTPs for all attributes and DMTs were calculated. Results A total of 508 patients were analyzed. Patients preferred DMTs with lower relapse rate, lower disability progression, lower severe adverse event, lower frequency of administration, and lower cost. In addition, they preferred oral DMTs. They were willing to pay $2,768, $289, $292, and $76 a month in exchange for every 1-time decrease in the number of relapses in two years, every 1% decrease in disability progression in two years, every 1% decrease in severe adverse events, and every 1-time decrease in the frequency of administration per month, respectively. The patients were willing to pay, in relation to market prices, between $7,020 and $134,934 per year for all DMTs, but interferon beta-1a SC. Conclusions Patients with MS considered relapse rate, disability progression, severe adverse events, route of administration, frequency of administration, and out-of-pocket cost, when they chose DMTs. Their WTPs for DMTs varied widely. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect